Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV

Journal of Medical Virology

Volumn 82, Issue 7, 2010, Pages 1150-1151

  Rachline, Anne ^a   Palmer, Pierre ^a,b   Simon, François ^a,b   Molina, Jean Michel ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

HCV; HIV; Short duration; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; NELFINAVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; MALE; MIXED INFECTION; TREATMENT DURATION; VIRUS LOAD; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG COMBINATION; HEPATITIS C, CHRONIC; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ADMINISTRATION, CUTANEOUS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954395166     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21781     Document Type: Article

References (11)

1. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, for the ANRS HCO2 RIBAVIC Study Team. 2004. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. J Am Med Assoc 292:2839-2848.
2. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, ven der Horst C, for the AIDS Clinical Trials Group A5071 Study Team. 2004. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451-459.
3. Flichman D, Cello J, Castaño G, Campos R, Sookoian S. 1999. In vivo down regulation of HIV replication after hepatitis Csuperinfection. Medicina (B Aires) 59:364-366.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
5. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
6. Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, Lopez-Serrano P, Cordero M, Portu J, Soriano V. 2008. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 22:15-21.
7. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C, EACS Executive Committee. 2008. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 9:82-88. (Pubitemid 351228130)
8. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators. 2007. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357:124-134. (Pubitemid 47057730)
9. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J, for the Euro SIDA Study Group. 2008. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198:1337-1344.
10. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C,Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, for the APRICOT Study Group. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis Cvirus infection in HIV-infected patients. N Engl J Med 351:438-450.
11. Yu ML, Dai CY, Lee LP, Hsieh MY, Hou NJ, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.2006. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther 11:1015-1019.